Sun Genomics Expands Testing Options for its Floré Gut Health Suite of Products | News

SAN DIEGO, January 10, 2022 (GLOBE NEWSWIRE) – Sun GenomicsCreator of Floré, the world’s only fully personalized precision probiotic, today announced that it is expanding its gut health testing options for its Floré product line in 2022. Company Founder and CEO Sunny Jain , will discuss the expansion during its presentation at the virtual fair Showcase of digital medicine and medical technologies January 10-19, 2022. Registered attendees can access Sun Genomics’ recorded corporate presentation on demand, at their convenience.

Sun Genomics announces three new clinical trials under its CLIA accredited laboratory. These tests, the Floré intestinal inflammation test, Flora Gastrointestinal Pathogen Testand Floré Heavy Metal Test are available on flora.com. As Sun Genomics continues to expand its testing capabilities, the company will help a wider population identify and treat a variety of intestinal health problems.

At the Digital Medicine & MedTech Showcase, Jain will discuss the science around gut microflora and elaborate on the connection between personal care and healthcare, especially as more and more people continue to consider their gut health. as an important factor in their overall health.

“The more we can create personalized probiotic solutions rooted in whole genome microflora test results, the better we can help the hundreds of millions of people with gut health issues,” Jain said. “As more people are empowered to take control of their gut health and more doctors realize the technology of testing, we believe gut microflora testing will become the new standard of care. . “

Digital Medicine & Medtech Showcase, as part of Biotech Showcase, is produced by Demy-Colton and EBD Group. The Showcase is an investor conference focused on advancing therapeutic development by providing a sophisticated networking platform for executives and investors fostering investment and partnership opportunities.

“We are thrilled that Sun Genomics is attending the Digital Medicine & Medtech Showcase this year,” said Sara Demy, CEO of Demy-Colton. “Digital Medicine & Medtech Showcase is a great opportunity for today’s cutting edge entrepreneurs and motivated investors to come together to discover the potential of technologies that will drive the future of the life science industry. Since its inception in 2016, Sun Genomics has served tens of thousands of customers with its Floré precision gut health offering. For more information on Sun Genomics, visit https://flore.com/.

ABOUT DIGITAL MEDICINE & MEDTECH SHOWCASE Digital Medicine & Medtech Showcase is part of Biotech Showcase, which is an investor and networking conference dedicated to providing private and public biotechnology and life science companies the opportunity to present and to meet investors and pharmaceutical executives in one location. Investors and biopharmaceutical executives around the world come together in this early warning week that sets the tone for the year ahead. Now in its 14th year, Biotech Showcase is a well-established and well-respected conference offering multiple avenues of business presentations, plenary sessions, workshops, networking, and an opportunity to schedule one-on-one meetings. Biotech Showcase and its family of events are produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high quality programs that support the wider biotechnology and life sciences industry.

ABOUT SUN GENOMICS Sun Genomics, headquartered in San Diego, California, is a leader in gut health. Founded in 2016, the company specializes in gut health testing and tailor-made supplements based on an individual’s gut microflora. This approach ensures that customers receive a fully personalized gut health supplement delivered as part of a monthly subscription. https://flore.com/

A photo accompanying this announcement is available on https://www.globenewswire.com/NewsRoom/AttachmentNg/f85aa08e-d984-47e9-83af-69a7c0f5991c

Media Contact Janine Warner Crowe PR sungenomics@crowepr.com (619) 794-0114, ext. 722

Copyright 2022 GlobeNewswire, Inc.

Comments are closed.